Cellular immune therapy for viral infections in transplant patients

被引:0
作者
Khanna, Rajiv [1 ]
Smith, Corey
机构
[1] QIMR Berghofer Med Res Inst, Dept Immunol, Brisbane, Qld 4006, Australia
关键词
Adoptive immunotherapy; CD4; cells; CMV; EBV; PTLD; solid organ transplant; transplant recipients; T cell therapy; viral infection; EPSTEIN-BARR-VIRUS; CYTOTOXIC T-LYMPHOCYTES; EX-VIVO EXPANSION; POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISEASE; ADENOVIRUS-SPECIFIC CD4(+); HUMAN CYTOMEGALOVIRUS; ADOPTIVE TRANSFER; CMV DISEASE; HUMAN POLYOMAVIRUSES; MEDIATED-IMMUNITY;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Stem cell and organ transplantation are considered as the major advances of modern medicine. Unfortunately the success of transplantation is limited by its toxicity and infectious complications as a result of profound immunosuppression. Viral infections are an extremely common and predictable problem in these patients. Antiviral drugs given either prophylactically or as early therapy for patients with detectable viral loads appear to be an effective strategy for reducing viral infections. However, long-term treatment with these drugs is associated with significant toxicity, expense and the appearance of drug resistant virus isolates ultimately resulting in treatment failure. Over the last few years, there is increasing evidence that cellular immune therapies can reverse the outgrowth of haematological malignancies and can also provide therapeutic benefit against lethal viral infections. While the expansion and adoptive transfer of virus-specific T-cells from the healthy donor can be an effective strategy to control viral replication, this is not possible when donors are seronegative or are subsequently inaccessible. Recent studies have demonstrated successful expansion of virus-specific T-cells from seropositive stem cell transplant recipients of a seronegative graft with active virus disease and the long term reconstitution of protective anti-viral immunity following their adoptive transfer back into the patients. Furthermore, this immunotherapeutic strategy has also been extended for multiple pathogens including cytomegalovirus, Epstein-Barr virus, adenovirus and BK polyoma-virus. This approach can be employed to rapidly expand multiple pathogens-specific T cells that can be used for adoptive immunotherapy. Finally, new assays to monitor T cell immunity have been developed which will allow to identify the high risk transplant patients who may develop virus-associated complications post-transplantation and can be given adoptive T cell therapy prophylactically.
引用
收藏
页码:796 / 807
页数:12
相关论文
共 103 条
  • [1] Longitudinal study of seroprevalence and serostability of the human polyomaviruses JCV and BKV in organ transplant recipients
    Antonsson, Annika
    Pawlita, Michael
    Feltkamp, Mariet C. W.
    Bavinck, Jan N. Bouwes
    Euvrard, Sylvie
    Harwood, Catherine A.
    Naldi, Luigi
    Nindl, Ingo
    Proby, Charlotte M.
    Neale, Rachel E.
    Waterboer, Tim
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2013, 85 (02) : 327 - 335
  • [2] Long-Term Outcomes of CMV Disease Treatment with Valganciclovir Versus IV Ganciclovir in Solid Organ Transplant Recipients
    Asberg, A.
    Humar, A.
    Jardine, A. G.
    Rollag, H.
    Pescovitz, M. D.
    Mouas, H.
    Bignamini, A.
    Toez, H.
    Dittmer, I.
    Montejo, M.
    Hartmann, A.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 (05) : 1205 - 1213
  • [3] Epstein-Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients
    Babcock, GJ
    Decker, LL
    Freeman, RB
    Thorley-Lawson, DA
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (04) : 567 - 576
  • [4] Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient
    Balduzzi, A.
    Lucchini, G.
    Hirsch, H. H.
    Basso, S.
    Cioni, M.
    Rovelli, A.
    Zincone, A.
    Grimaldi, M.
    Corti, P.
    Bonanomi, S.
    Biondi, A.
    Locatelli, F.
    Biagi, E.
    Comoli, P.
    [J]. BONE MARROW TRANSPLANTATION, 2011, 46 (07) : 987 - 992
  • [5] BK Virus-Specific T Cells for Use in Cellular Therapy Show Specificity to Multiple Antigens and Polyfunctional Cytokine Responses
    Blyth, Emily
    Clancy, Leighton
    Simms, Renee
    Gaundar, Shivashni
    O'Connell, Philip
    Micklethwaite, Kenneth
    Gottlieb, David J.
    [J]. TRANSPLANTATION, 2011, 92 (10) : 1077 - 1084
  • [6] Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients
    Boivin, G
    Goyette, N
    Gilbert, C
    Humar, A
    Covington, E
    [J]. TRANSPLANT INFECTIOUS DISEASE, 2005, 7 (3-4) : 166 - 170
  • [7] Immunotherapy targeting EBV-expressing lymphoproliferative diseases
    Bollard, Catherine M.
    Cooper, Laurence J.
    Heslop, Helen E.
    [J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2008, 21 (03) : 405 - 420
  • [8] T-cell therapy in the treatment of post-transplant lymphoproliferative disease
    Bollard, Catherine M.
    Rooney, Cliona M.
    Heslop, Helen E.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (09) : 510 - 519
  • [9] Adoptive immunotherapy for posttransplantation viral infections
    Bollard, CM
    Kuehnle, I
    Leen, A
    Rooney, CM
    Heslop, HE
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2004, 10 (03) : 143 - 155
  • [10] Human polyoma viruses and disease with emphasis on clinical BK and JC
    Boothpur, Raghavender
    Brennan, Daniel C.
    [J]. JOURNAL OF CLINICAL VIROLOGY, 2010, 47 (04) : 306 - 312